The World Health Organization (WHO) has identified bedside oxygen concentrators as essential medical devices for COVID-19 in regions lacking liquid oxygen and PSA (pressure swing adsorption) plants. While oxygen plants require massive investment in infrastructure, oxygen concentrators are self-contained, electrically powered medical devices that can continually produce more than 90% oxygen from room air at the patient bedside.
Oxygen concentrators, however, do require frequent maintenance and an uninterrupted power supply. To meet projected need, the O2 Challenge will require that oxygen concentrators be produced at low cost, be rapidly manufacturable, contain an uninterruptible power supply and be easily serviced. The devices will conform to WHO specifications for oxygen concentrators for the management of COVID-19.